Parabilis Medicines, Inc. cash flow to debt ratio of 0.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Parabilis Medicines, Inc. has insufficient data to evaluate this check.

Parabilis Medicines, Inc. has insufficient data to evaluate this check.

Parabilis Medicines, Inc. has insufficient data to evaluate this check.

Parabilis Medicines, Inc. has negative EBITDA, making leverage ratio unreliable

Parabilis Medicines, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Parabilis Medicines, Inc. has insufficient data to evaluate this check.

Parabilis Medicines, Inc. has insufficient data to evaluate this check.

Parabilis Medicines, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Parabilis Medicines, Inc.'s return on equity of -15.14%, is lower than 15.00%, indicating bad performance

Parabilis Medicines, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Parabilis Medicines, Inc. has insufficient public price history to evaluate earnings stability.

Parabilis Medicines, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Parabilis Medicines, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Parabilis Medicines, Inc.'s yearly earnings has decreased 23.72% since last year from $-117.91M to $-145.89M, signaling decreasing performance

Parabilis Medicines, Inc. has insufficient data to evaluate this check.

ROIC -8.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Parabilis Medicines, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Parabilis Medicines, Inc. has insufficient public price history to evaluate revenue consistency.

Parabilis Medicines, Inc. has insufficient public price history to evaluate ROE consistency.

Parabilis Medicines, Inc. has insufficient data to evaluate this check.

Parabilis Medicines, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Parabilis Medicines, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Parabilis Medicines, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Parabilis Medicines, Inc. has insufficient data to evaluate this check.

Parabilis Medicines, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Parabilis Medicines, Inc. has a price-to-book ratio of 1.08x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Parabilis Medicines, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue